U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498595) titled 'TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC' on March 16.
Brief Summary: This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Intervention:
DRUG: TILs infusion
Experimental: Surgically collect fresh tumor tissue or malignant pleural effusion to isolate immune cells, and prepare TILs Infusion. Trial product: TILs Injection. Administration route: Intravenous Infusion...